Avicor, reported by HVG (Weekly World Economy) the Hungarian leading economic and political weekly, is working on synthetizing potential drug candidate molecules which inhibit the enzyme responsible for the viral entry of Covid-19 together with a German company.
[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ _module_preset=”default” hover_enabled=”0″ admin_label=”címsor”] Avicor Ltd. successfully developed several new products in the frame of a Hungarian R&D grant (KFI_16-1-2017-0105) for specific enrichment of nucleic acids deriving from diverse biological samples specific for human, bacterial, fungal and viral nucleic acids. [/et_pb_text][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left”
Electron paramagnetic resonance spectroscopic studies of the electron transfer reaction of Hantzsch ester and a pyrylium salt
The most serious and currently incurable chronic pulmonary disease besides lung cancer is COPD (chronic obstructive pulmonary disease), which is also a national disease in Hungary, registering 15-16 thousand of new patients a year, with an estimated total number of patients over 600 000.